Altamira Therapeutics Ltd

2QA

Company Profile

  • Business description

    Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy, viral infections, and inner ear disorders. Its product Bentrio, is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows for the delivery of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.

  • Contact

    2 Church Street
    Clarendon House
    HamiltonHM11
    BMU

    T: +1 441 295-5950

    E: [email protected]

    https://www.altamiratherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.
stocks

Revenue growth on track for undervalued ASX healthcare stock

Near-term cost growth does not change our long-term view.
stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,151.3029.500.32%
CAC 408,245.8018.07-0.22%
DAX 4023,806.99273.64-1.14%
Dow JONES (US)48,185.80275.880.58%
FTSE 10010,603.485.40-0.05%
HKSE25,950.55198.150.77%
NASDAQ22,822.42187.420.83%
Nikkei 22556,941.421,046.101.87%
NZX 50 Index13,181.4492.37-0.70%
S&P 5006,824.6641.850.62%
S&P/ASX 2008,956.9032.500.36%
SSE Composite Index3,998.5632.390.82%

Market Movers